Pfizer, Inc. (PFE) Stake Maintained by Moody National Bank Trust Division
Moody National Bank Trust Division continued to hold its stake in Pfizer, Inc. (NYSE:PFE) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,903 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Pfizer accounts for approximately 0.2% of Moody National Bank Trust Division’s investment portfolio, making the stock its 8th largest holding. Moody National Bank Trust Division’s holdings in Pfizer were worth $3,894,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in PFE. D. Scott Neal Inc. lifted its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC acquired a new position in shares of Pfizer in the first quarter worth approximately $121,000. Cascade Investment Advisors Inc. lifted its stake in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 2,200 shares during the period. Patten Group Inc. lifted its stake in shares of Pfizer by 5.1% in the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 252 shares during the period. Finally, Acropolis Investment Management LLC lifted its stake in shares of Pfizer by 6.7% in the second quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock worth $188,000 after acquiring an additional 352 shares during the period. 68.98% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms recently commented on PFE. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets reaffirmed a “buy” rating and issued a $39.00 price objective (up from $37.00) on shares of Pfizer in a research note on Thursday. Berenberg Bank set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research note on Tuesday, October 3rd. Finally, Cowen and Company set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. Pfizer has an average rating of “Hold” and a consensus target price of $38.26.
In related news, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by corporate insiders.
Shares of Pfizer, Inc. (PFE) opened at 36.24 on Friday. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $36.60. The company has a market cap of $215.53 billion, a P/E ratio of 26.51 and a beta of 1.00. The stock’s 50 day moving average price is $35.49 and its 200 day moving average price is $33.82.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter last year, the company earned $0.64 EPS. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.53%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.